DK3269717T5 - Polymorfe og pseudopolymorfe former af den farmaceutiske sammensætning NXL104 - Google Patents

Polymorfe og pseudopolymorfe former af den farmaceutiske sammensætning NXL104 Download PDF

Info

Publication number
DK3269717T5
DK3269717T5 DK17182561.5T DK17182561T DK3269717T5 DK 3269717 T5 DK3269717 T5 DK 3269717T5 DK 17182561 T DK17182561 T DK 17182561T DK 3269717 T5 DK3269717 T5 DK 3269717T5
Authority
DK
Denmark
Prior art keywords
nxl104
polymorphic
pharmaceutical composition
pseudopolymorphic forms
pseudopolymorphic
Prior art date
Application number
DK17182561.5T
Other languages
English (en)
Other versions
DK3269717T3 (da
DK3269717T4 (da
Inventor
Sisir Bhattacharya
Alain Bonnet
Mahendra G Dedhiya
Véronique Ducandas
Alexandre Giuliani
Alain Priour
Valérie Ravaux
Peter Spargo
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42154208&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3269717(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Publication of DK3269717T3 publication Critical patent/DK3269717T3/da
Application granted granted Critical
Publication of DK3269717T4 publication Critical patent/DK3269717T4/da
Publication of DK3269717T5 publication Critical patent/DK3269717T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK17182561.5T 2009-10-09 2010-10-08 Polymorfe og pseudopolymorfe former af den farmaceutiske sammensætning NXL104 DK3269717T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0904864A FR2951171A1 (fr) 2009-10-09 2009-10-09 Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
US26366309P 2009-11-23 2009-11-23
EP10762934.7A EP2486038B1 (en) 2009-10-09 2010-10-08 Polymorphic and pseudopolymorphic forms of a pharmaceutical compound

Publications (3)

Publication Number Publication Date
DK3269717T3 DK3269717T3 (da) 2019-04-23
DK3269717T4 DK3269717T4 (da) 2023-06-26
DK3269717T5 true DK3269717T5 (da) 2023-11-27

Family

ID=42154208

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17182561.5T DK3269717T5 (da) 2009-10-09 2010-10-08 Polymorfe og pseudopolymorfe former af den farmaceutiske sammensætning NXL104

Country Status (22)

Country Link
US (5) US8471025B2 (da)
EP (3) EP3505518A1 (da)
JP (4) JP6072540B2 (da)
KR (4) KR101817811B1 (da)
CN (3) CN104592229A (da)
AU (1) AU2010304974B2 (da)
BR (2) BR112012007976B1 (da)
CA (1) CA2716914C (da)
CY (1) CY1121583T1 (da)
DK (1) DK3269717T5 (da)
ES (2) ES2645110T3 (da)
FI (1) FI3269717T4 (da)
FR (1) FR2951171A1 (da)
HU (1) HUE043086T2 (da)
IL (3) IL218565A0 (da)
MX (1) MX2012003730A (da)
MY (1) MY174776A (da)
PL (1) PL3269717T5 (da)
PT (1) PT3269717T (da)
RU (1) RU2727509C2 (da)
SI (1) SI3269717T2 (da)
WO (1) WO2011042560A1 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2753387C (en) * 2009-02-23 2017-01-24 Forest Laboratories Holdings Limited Novel cephem compounds useful for the treatment of bacterial infections
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
WO2012086241A1 (ja) * 2010-12-22 2012-06-28 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 光学活性なジアザビシクロオクタン誘導体およびその製造法
AU2012270051B2 (en) 2011-06-17 2016-12-22 Pfizer Anti-Infectives Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
CN103687598B (zh) * 2011-07-26 2016-03-16 沃克哈特有限公司 包括舒巴坦和β-内酰胺酶抑制剂的药物组合物
CA2833241C (en) * 2011-08-27 2015-05-12 Wockhardt Limited 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections
MX349827B (es) 2011-09-13 2017-08-14 Wockhardt Ltd Compuestos que contienen nitrogeno y su uso.
US8969567B2 (en) 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
CA2869051A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. Isoxazole .beta.-lactamase inhibitors
US8940897B2 (en) 2012-03-30 2015-01-27 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole β-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
BR112014029368B1 (pt) * 2012-05-30 2020-10-27 Meiji Seika Pharma Co., Ltd inibidor de beta-lactamase e processo para preparar o mesmo
KR101763056B1 (ko) * 2013-03-08 2017-07-28 욱크하르트 리미티드 (2s,5r)-2-카복스아미도-7-옥소-6-설포옥시-1,6-디아자-비사이클로[3.2.1]옥탄의 나트륨염을 위한 방법
RU2625304C2 (ru) * 2013-03-08 2017-07-13 Вокхардт Лимитед Способ получения (2s,5r)-7-оксо-6-сульфоокси-2-[((3r)-пирролидин-3-карбонил)гидразинокарбонил]-1,6-диазабицикло[3.2.1]октана
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
EP3050883B1 (en) 2013-09-24 2020-04-22 Meiji Seika Pharma Co., Ltd. Production method for diazabicyclooctane derivatives and intermediates
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
BR122022016622B1 (pt) 2013-10-08 2023-11-07 Meiji Seika Pharma Co., Ltd. Formas cristalinas de derivado de diazabiciclo-octano, seus processos de produção e uso das mesmas
EP3107539A1 (en) * 2014-02-20 2016-12-28 Wockhardt Limited Pharmaceutical combinations comprising antibacterial agents
EP3212238A1 (en) 2014-10-28 2017-09-06 Sandoz AG Pharmaceutical composition consisting of ceftaroline fosamil acetic acid solvate particles and arginine particles, both having a specific particle size distribution
PT3221313T (pt) 2014-11-17 2019-04-15 Entasis Therapeutics Ltd Terapia combinada para tratamento de infecções bacterianas resistentes
ES2821826T3 (es) 2014-12-05 2021-04-27 Meiji Seika Pharma Co Ltd Método para producir cristales de derivado de diazabiciclooctano y preparación liofilizada estable
CA2990546A1 (en) * 2015-08-10 2017-02-16 Sandoz Ag Form c of avibactam sodium
CN107325096B (zh) * 2016-04-29 2020-11-03 正大天晴药业集团股份有限公司 一种阿维巴坦单钠盐的结晶
CN109641901B (zh) * 2016-08-26 2022-12-09 桑多斯股份公司 阿维巴坦游离酸
MX2021010077A (es) 2016-09-16 2022-05-23 Entasis Therapeutics Ltd Compuestos inhibidores de beta-lactamasa.
CN107880042A (zh) * 2016-09-30 2018-04-06 上海复星星泰医药科技有限公司 阿维巴坦钠及其中间体化合物的制备方法
CN110267956B (zh) * 2017-02-08 2022-07-15 桑多斯股份公司 用于制备阿维巴坦钠结晶形式c的方法
SI3630111T1 (sl) 2017-05-08 2022-05-31 Entasis Therapeutics, Inc. Spojine in postopki za zdravljenje bakterijskih okužb
TW201920174A (zh) * 2017-09-27 2019-06-01 瑞士商羅氏大藥廠股份有限公司 二氮雜雙環辛烷衍生物之醫藥形式及其製法
EP3687992A1 (en) * 2017-09-27 2020-08-05 Meiji Seika Pharma Co., Ltd. Crystalline forms of diazabicyclooctane derivatives and production process thereof
CA3076955A1 (en) * 2017-09-27 2019-04-04 Fedora Pharmaceuticals Inc. Pharmaceutical forms of diazabicyclooctane derivatives and process for producing the same
CN107501265B (zh) * 2017-10-09 2019-05-28 台州职业技术学院 一种7-氧代-二氮杂二环[3,2,1]辛烷衍生化合物及其制备方法和应用
CN109678856B (zh) 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
CN107827886B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种高纯度阿维巴坦的精制制备工艺
CN109956941B (zh) * 2017-12-25 2020-08-04 新发药业有限公司 一种阿维巴坦的简便制备方法
CN107935945A (zh) * 2018-01-12 2018-04-20 上海龙翔生物医药开发有限公司 一种通过反应制备晶型a或晶型d阿维巴坦产品的方法
CN107936017A (zh) * 2018-01-12 2018-04-20 上海龙翔生物医药开发有限公司 一种通过结晶制备晶型a或晶型d阿维巴坦产品的方法
CN110078728B (zh) * 2019-05-23 2020-10-23 江西富祥药业股份有限公司 一种阿维巴坦中间体、制备方法及其应用
CN113105455B (zh) * 2020-01-10 2024-05-17 四川科伦药物研究院有限公司 晶型b阿维巴坦钠的制备方法
CN111689964A (zh) * 2020-07-21 2020-09-22 海南海灵化学制药有限公司 一种阿维巴坦纳的稳定晶型以及制备方法
CN115677697A (zh) * 2022-09-19 2023-02-03 瑞阳制药股份有限公司 粒度可调控且流动性好的b晶型阿维巴坦钠析晶方法
KR20240041506A (ko) * 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018129A1 (en) * 1993-12-29 1995-07-06 Pfizer Inc. Diazabicyclic neurokinin antagonists
TW473479B (en) 1997-12-19 2002-01-21 Takeda Chemical Industries Ltd Phosphonocephem derivatives, their production and use
AU2930501A (en) * 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
CN1189471C (zh) 2000-08-10 2005-02-16 武田药品工业株式会社 膦酰基头孢烯化合物
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
EP2068958B1 (en) * 2006-09-28 2016-10-19 Cook Medical Technologies LLC Medical device including an anesthetic and method of preparation thereof
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
EP2921559A1 (en) 2008-06-19 2015-09-23 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
KR20120083344A (ko) * 2009-09-21 2012-07-25 아스트라제네카 아베 세프타롤린을 사용한 박테리아 감염 치료용 조성물 및 방법

Also Published As

Publication number Publication date
IL239663A0 (en) 2015-08-31
IL259296A (en) 2018-07-31
AU2010304974A1 (en) 2012-04-05
US8471025B2 (en) 2013-06-25
PT3269717T (pt) 2019-05-16
JP2016029082A (ja) 2016-03-03
EP3269717B1 (en) 2019-02-27
BR122019021689B8 (pt) 2021-05-25
BR112012007976B1 (pt) 2020-03-03
JP6197170B2 (ja) 2017-09-20
US9062053B2 (en) 2015-06-23
RU2015137928A3 (da) 2019-04-04
ES2721228T5 (es) 2023-10-30
KR20180067717A (ko) 2018-06-20
CA2716914A1 (en) 2011-04-09
EP3269717B2 (en) 2023-06-14
RU2015137928A (ru) 2018-12-25
JP2017149754A (ja) 2017-08-31
FR2951171A1 (fr) 2011-04-15
ES2721228T3 (es) 2019-07-29
DK3269717T3 (da) 2019-04-23
JP6072540B2 (ja) 2017-02-01
JP2018123151A (ja) 2018-08-09
JP6630391B2 (ja) 2020-01-15
IL218565A0 (en) 2012-05-31
MY174776A (en) 2020-05-14
EP3269717B9 (en) 2023-08-09
EP2486038A1 (en) 2012-08-15
ES2645110T3 (es) 2017-12-04
CN102834395A (zh) 2012-12-19
KR101817811B1 (ko) 2018-01-11
RU2012118247A (ru) 2013-11-20
US8835455B2 (en) 2014-09-16
AU2010304974B2 (en) 2014-10-23
US20110152311A1 (en) 2011-06-23
SI3269717T1 (sl) 2019-05-31
US20140349967A1 (en) 2014-11-27
CN109824668A (zh) 2019-05-31
EP2486038B1 (en) 2017-08-30
DK3269717T4 (da) 2023-06-26
FI3269717T4 (fi) 2023-08-31
WO2011042560A1 (en) 2011-04-14
CN104592229A (zh) 2015-05-06
IL259296B (en) 2021-10-31
KR20200010586A (ko) 2020-01-30
MX2012003730A (es) 2012-10-03
RU2727509C2 (ru) 2020-07-22
CY1121583T1 (el) 2020-05-29
US20170210742A1 (en) 2017-07-27
HUE043086T2 (hu) 2019-08-28
US20150246920A1 (en) 2015-09-03
US20130267480A1 (en) 2013-10-10
SI3269717T2 (sl) 2023-09-29
CN102834395B (zh) 2016-06-29
JP6321853B2 (ja) 2018-05-09
KR20120106720A (ko) 2012-09-26
EP3505518A1 (en) 2019-07-03
CA2716914C (en) 2020-10-27
PL3269717T5 (pl) 2023-09-18
JP2013507346A (ja) 2013-03-04
BR122019021689B1 (pt) 2020-10-27
PL3269717T3 (pl) 2019-07-31
US9580424B2 (en) 2017-02-28
EP3269717A1 (en) 2018-01-17
KR20170134791A (ko) 2017-12-06

Similar Documents

Publication Publication Date Title
DK3269717T5 (da) Polymorfe og pseudopolymorfe former af den farmaceutiske sammensætning NXL104
SMT201700095B (is) Composizioni farmaceutiche per inalazione
BRPI1011587A2 (pt) compostos e composições terapèuticas
DK2513193T3 (da) Forbedrede blends af polyarylenethere og polyarylensulfider
DK3460056T3 (da) Terapeutiske nukleasesammensætninger og fremgangsmåder
DK3097925T3 (da) Farmaceutisk sammensætning
DK3045043T3 (da) Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
BRPI0906980A2 (pt) Composição de derivados e maleatados
FR22C1023I1 (fr) Forme polymorphe st-246 et procedes de preparation
DK2220116T3 (da) Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
DK2498756T3 (da) Tabletformuleringer af neratinibmaleat
DK2264042T3 (da) Mikronisering af polyoler
DK2419732T3 (da) Prionfrie nanopartikelsammensætninger og fremgangsmåder
DK3092901T3 (da) Quinolonanaloger og fremgangsmåder relateret dertil
BRPI1015939A2 (pt) composição farmacêutica
BRPI1012539A2 (pt) composições farmacêuticas
BRPI0810179A2 (pt) Composições de oligo-guluronato e galacturonato
DK3260118T3 (da) Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
FI20096058A0 (fi) Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
BRPI1006229A2 (pt) composição incluindo uma quantidade suficiente de curcumina
BR112012010242A2 (pt) derivados de heteroarilpiperidina e heteroarilpiperazina
IT1394400B1 (it) Composizioni farmaceutiche
DK2475649T3 (da) Indenonderivat og farmaceutisk sammensætning omfattende samme
DK2391349T3 (da) Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater